Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
15.23
+0.63 (4.32%)
At close: Mar 4, 2026, 4:00 PM EST
15.30
+0.07 (0.46%)
After-hours: Mar 4, 2026, 7:56 PM EST
Dyne Therapeutics Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for Dyne Therapeutics stock have an average target of 38.63, with a low estimate of 16 and a high estimate of 50. The average target predicts an increase of 153.64% from the current stock price of 15.23.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Dyne Therapeutics stock from 16 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 7 | 7 | 7 |
| Buy | 6 | 6 | 9 | 9 | 9 | 8 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 15 | 17 | 17 | 17 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $50 → $47 | Buy | Maintains | $50 → $47 | +208.60% | Mar 3, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $38 | Strong Buy | Maintains | $38 | +149.51% | Mar 3, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $60 → $50 | Strong Buy | Maintains | $60 → $50 | +228.30% | Mar 3, 2026 |
| JP Morgan | JP Morgan | Hold Maintains $17 → $16 | Hold | Maintains | $17 → $16 | +5.06% | Jan 20, 2026 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $38 → $36 | Buy | Maintains | $38 → $36 | +136.38% | Dec 15, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
68.07M
EPS This Year
-3.30
from -3.47
EPS Next Year
-3.04
from -3.30
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | 208.7M | |||
| Avg | n/a | 68.1M | |||
| Low | n/a | 19.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.44 | -1.73 | |||
| Avg | -3.30 | -3.04 | |||
| Low | -4.23 | -4.69 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.